Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01435408
NCT01435408
Active, not recruiting
Not Applicable

A Randomised Comparison of the Clinical Outcome After Postconditioning or Deferred Stent Implantation Versus Conventional Treatment

Rigshospitalet, Denmark5 sites in 1 country2,000 target enrollmentApril 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsST Segment Elevation Myocardial Infarction

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ST Segment Elevation Myocardial Infarction
Sponsor
Rigshospitalet, Denmark
Enrollment
2000
Locations
5
Primary Endpoint
All cause mortality, heart failure (postconditioning)
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This study focuses on Cardioprotective strategies.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
December 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Thomas Engstrom

MD, DMSci, PhD

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • •Age ≥ 18 years.
  • •Acute onset of chest pain of \< 12 hours' duration.
  • •ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block.
  • •Culprit lesion in a major native vessel.

Exclusion Criteria

  • •Pregnancy.
  • •Known intolerance of ASA, clopidogrel, heparin or contrast.
  • •Inability to understand information or to provide informed consent.
  • •Haemorrhagic diathesis or known coagulopathy.
  • •Stent thrombosis.

Outcomes

Primary Outcomes

All cause mortality, heart failure (postconditioning)

Time Frame: 2 years

Secondary Outcomes

  • All cause mortality, myocardial infarction, repeat revascularisation and occurrence of definite stent thrombosis according to ARC definition within 1 year (deferred stent strategy)(1 year)
  • Infarct size in relation to area at risk as determined by MRI after 3 month(3 month)

Study Sites (5)

Loading locations...

Similar Trials

Completed
Phase 4
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk FactorsHypertensionHypercholesterolemia
NCT00407537Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,531
Completed
Not Applicable
A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failureHyperuricemia in patients with chronic heart failure
JPRN-C000000426ational Cardiovascular Center213
Completed
Not Applicable
Evaluation of Cardiovascular Health Outcomes Among SurvivorsCardiovascular RiskCancer
NCT01003574St. Jude Children's Research Hospital509
Completed
Not Applicable
Efficacy of intracoronary abciximab in percutaneous coronary interventioST-segment elevation myocardial infarction.myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onset
IRCT2012081310573N1Cardiovascular Research Center, Shahid Beheshti University of Medical sciences40
Not yet recruiting
Phase 3
A COMPARASON OF EFFECTS OF KETAMINE-DEXMEDETOMIDINEVERSUS FENTANYL-PROPOFOL IN PATIENTS UNDERGOING CARDIACSURGERY FOR MYOCARDIAL PROTECTIOHealth Condition 1: O- Medical and Surgical
CTRI/2024/07/071613SMS Medical College and Hospital